The introduction of treatments targeting HER2 has resulted in considerable advancements in the outcomes for patients diagnosed with HER2-positive breast cancer (as determined by IHC 3+ or IHC 2+ with a positive ISH result) [9]. This evidence concerns the gene ERBB2 and breast carcinoma.